Thursday, May 19, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

History, facts and the future

by Medical Finance
in Coronavirus
Crucial regulator of malaria parasite transmission identified
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

mRNA vaccine technology is a field full of promise – as well as unanswered questions – for communities living with the burden of the world’s most deadly infectious diseases.

Despite appearances, mRNA technology is not new. But ever since mRNA vaccines burst onto the global scene to take on COVID-19, a wealth of possibilities has opened up as research teams explore ways to harness mRNA technology to tackle other global health concerns.

The ‘Big Three’ infectious diseases

Tuberculosis, malaria and HIV are known as the ‘Big Three’ infectious diseases: they are the deadliest communicable diseases in the world. Together, they killed more than 2.8 million people in 2020, according to World Health Organization (WHO) figures. Initial data suggests there were 1.8 million COVID-19 deaths in 2020, although the WHO estimates the number could be “at least” 3 million.

Beyond the deaths caused by the Big Three, almost 290 million people were living with HIV, malaria or TB in 2020. These conditions are known as diseases of poverty. They disproportionately affect developing countries, and they are both a result of and a cause of poverty.

A total of 1.5 million people died from TB in 2020. Globally, it is the second leading infectious killer after COVID-19. An estimated 10 million people fell ill with TB in 2020 – 5.6 million men, 3.3 million women and 1.1 million children. Just eight countries accounted for two-thirds of the total number of TB cases: India has the highest burden, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa.

Around 627,000 people died of malaria in 2020, with an estimated 241 million cases reported worldwide. Africa carries the majority of the world’s malaria burden – 95 per cent of malaria cases and 96 per cent of malaria deaths. About 80 per cent of malaria infections in this region were in children under five.

Meanwhile, in 2020, 680,000 people died from HIV-related causes. There were 1.5 million new cases of HIV in 2020, while worldwide there were an estimated 37.7 million people living with HIV. The majority of people living with the virus – 25.4 million – are in Africa.

History of messenger ribonucleic acids

mRNA technology has been in development since the 1960s, but it was proven responsive when SARS-CoV-2 hit the world. Its success in combatting COVID-19 has resulted in renewed interest in developing the technology for other diseases.

In a nutshell, mRNAs are messenger ribonucleic acids that elicit an immune response from cells before degrading. They work by introducing a sequence that is coded for a disease-specific antigen – a substance that causes the body to make antibodies against it; once this antigen is produced within the body, the immune system can recognise it and get ready to fight the real virus, bacteria or parasite.

Before the COVID-19 pandemic, exploration into mRNA vaccines for a range of diseases had begun, including Ebola, Zika and rabies, as well as cancers and influenza.

But the field has developed rapidly in the past few years. In a 2018 review, US-based scientists said that mRNA vaccines represented a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration.

“The mRNA vaccine field is developing extremely rapidly; a large body of preclinical data has accumulated over the past several years, and multiple human clinical trials have been initiated,” the scientists said. “The data suggest that mRNA vaccines have the potential to solve many of the challenges in vaccine development for both infectious diseases and cancer.”

Why is mRNA technology so exciting?

Interest in mRNA technology has exploded since it entered the mainstream during the COVID-19 pandemic. The full text of one 2020 review of mRNA technology from researchers in Shanghai and Beijing has been viewed around 35,000 times and has more than 40 citations, giving it a high impact factor in the world of scientific literature.

mRNA vaccines appear promising because of the speed with which they can be developed and produced, and their flexibility and adaptability to variants. The US pharmaceutical company Moderna’s mRNA vaccine against SARS-CoV-2 began clinical trials 63 days after the publication of the virus’ genome. By comparison, the Gardasil vaccine for human papillomavirus (HPV) – which uses recombinant DNA technology – took 15 years to be approved for use, in 2006.

Developments in the stability of mRNA vaccines led to the massive increase in interest in the technology. mRNA vaccines were tested in the early 1990s but there were concerns about the scale of production and their fragile stability, according to a 2019 study.

With advances in the synthetic production of mRNAs, the technology became more attractive. Other forms of safe and effective vaccines carry a weakened virus or a part of the virus, and growing the volume of pathogens required to produce immunisations on a large scale, and then weakening the virus, takes time.

With the Coalition for Epidemic Preparedness Innovations (CEPI) setting the world the task of generating vaccines within 100 days of identifying a new germ, research and development groups – including a team at the University of Oxford that has produced a pre-print 100-day vaccine blueprint – say they are up to the challenge.

The future of mRNA vaccine technology

In the first months of 2022 there was a flurry of activity surrounding mRNA technology transfer and development, with the WHO announcing additional locations for its mRNA vaccine technology transfer hubs, and German biotechnology company BioNTech designating sites for new production facilities in Africa.

Amid these announcements, global health leaders and scientists pointed out, time and again, the potential for mRNA to take on the Big Three diseases, as well as non-communicable health burdens such as cancer.

And clinical trials have already begun, or are expected to begin this year, for mRNA vaccine candidates for HIV, malaria, and tuberculosis.

But scientists are tempering their optimism with caution, as reaching the clinical trial stage does not always guarantee a vaccine candidate will be proven safe and effective. And global health advocates say that funding for vaccine research and development, and an ongoing focus on technology transfer and knowledge strengthening in the global South, must continue apace.

The recipes for COVID-19 mRNA vaccines have been tightly held by pharmaceutical companies, who refuse to share patents with developing countries. To combat “vaccine hoarding” and global health inequality, the WHO and a consortium of research organisations and the Medicines Patent Pool banded together in 2021 to unlock the structure of the mRNA vaccines, establishing the first mRNA research centre and transfer hub in South Africa, with ‘spokes’ in Brazil and Argentina.

In February, the WHO announced that six additional countries in Sub-Saharan Africa and North Africa would receive technology to enable them to manufacture COVID-19 vaccines as part of the initiative.

The WHO said that mRNA technology could also be used for insulin to treat diabetes, cancer medicines and, potentially, vaccines for the Big Three deadly infectious diseases. Ultimately, said the WHO, the mRNA tech transfer hubs will promote access to vaccines for everyone, strengthen health security and promote self-reliance for the future.

Kate Stegeman, Africa region advocacy coordinator for the Doctors Without Borders (MSF) Access Campaign, said that diversifying mRNA vaccine manufacturing capacity to low- and middle-income countries should be a global health priority. She said: “More regions producing mRNA vaccines as essential preparedness against infectious diseases could bolster the response not only to COVID-19 and future infectious diseases, but also potentially to existing ones such as malaria, tuberculosis, and HIV.”

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Endemicity is not a victory: the unmitigated downside risks of widespread SARS-CoV-2 transmission. Image Credit: FrankHH / Shutterstock

downside risks of widespread SARS-CoV-2 transmission

by Medical Finance
May 19, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers evaluated the impact of changes in infection fatality rate...

Study: Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2. Image Credit: CROCOTHERY/Shutterstock

Investigating extensive SARS-CoV-2 neutralizing immunoglobulins from COVID-19 recovered subjects

by Medical Finance
May 19, 2022
0

A recent study posted to the bioRxiv* preprint server discovered immunoglobulins (Igs) with powerful broad-acting neutralizing capacity against severe acute respiratory...

Study: Broad SARS-CoV-2 spike-specific CD4+ T-cell response preserves recognition of variants of concern. Image Credit: Naeblys/Shutterstock

Study characterizes SARS-CoV-2 spike-specific cluster of differentiation 4+ T-cell response

by Medical Finance
May 19, 2022
0

In a recent study posted to the Research Square* preprint server, and currently under consideration at a Nature Portfolio Journal, researchers...

Study: SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine. ​​​​​​​Image Credit: NIAID

Study on the efficacy of a BNT162b2 booster dose in the elderly

by Medical Finance
May 19, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers characterized the immune responses against severe acute respiratory syndrome...

Study: Long-term psychological consequences of long Covid: a propensity score matching analysis comparing trajectories of depression and anxiety symptoms before and after contracting long Covid vs short Covid. Image Credit: Starocean/Shutterstock

Study explores long-lasting psychological implications of long COVID

by Medical Finance
May 19, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers evaluated the long-standing psychological manifestations of long coronavirus disease (long...

Study: Genetic surveillance of SARS-CoV-2 Mpro reveals high sequence and structural conservation prior to the introduction of protease inhibitor Paxlovid. Image Credit NIAID

Framework for genomic surveillance of SARS-CoV-2 Mpro evolution

by Medical Finance
May 19, 2022
0

A recent study posted to the bioRxiv* preprint server investigated the active genetic evolution of severe acute respiratory syndrome coronavirus...

Next Post
Study: SARS-CoV-2 Infections in Professional Orchestra and Choir Musicians – A Prospective Cohort Study. Image Credit: Skreidzeleu/Shutterstock

Incidence of SARS-CoV-2 infections in orchestra and choir musicians

Study: NRP1 and furin as putative mediators of SARS-CoV-2 entry into human brain cells. Image Credit: Kateryna Kon/Shutterstock

Researchers discover mechanism behind SARS-CoV-2 entry into the brain

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. Image Credit: Pong Ch / Shutterstock
    Researchers identify a potent new combination of antiviral drugs to combat SARS-CoV-2
  • Study: USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING. Image Credit: Juan Gaertner / Shutterstock
    USP22 crucial for type III interferon signaling and SARS-CoV-2 infection
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply